The combinations are also approved for relapsed or refractory multiple myeloma in Japan, the UK and other markets including ...

Just when the future looked bleak for GSK’s Blenrep comeback in the U.S., the FDA has blessed the company's multiple myeloma ...

European Union approves GSK’s Blenrep combinations to treat relapsed/refractory multiple myeloma: London, UK Saturday, July 26, 2025, 11:00 Hrs [IST] GSK plc announced the appro ...

In an import contrast to events in the USA, UK pharma major GSK late Thursday announced the approval of Blenrep (belantamab ...

GSK announced today that Health Canada has approved Blenrep (belantamab mafodotin for injection) in combination with ...

GSK (GSK) stock in focus as the company secures EU approval for Blenrep combo therapies targeting the blood cancer multiple ...

GSK’s Blenrep (belantamab mafodotin) combinations have been approved by the European Commission (EC) to treat adults with relapsed or refractory multiple myeloma.

The US Food and Drug Administration (FDA) has extended the review period for the Biologics License Application (BLA) for ...

The new target action date for Blenrep, which GSK is proposing for the second-line treatment of relapsed or refractory multiple myeloma, is Oct. 23.

The European Union has given regulatory approval to GSK's drug, Blenrep, for treating relapsed or treatment-resistant forms of blood plasma cell cancer.

Last week, an FDA advisory committee against the risk-benefit profile of Blenrep in combination with other therapies. Regulators and reviewers were concerned about the ocular side effects and dosing ...

And other biotech news brought to you by The Readout.